Inflammation and Heart Failure Oka et al Nature. 2012; 485:251-255. M itochondria are derived from primordial bacterial endosymbionts and retain partial genomes. In mammalian cells, damaged or dysfunctional mitochondria are recognized, targeted for elimination, then neatly packaged and eliminated via mitophagy. A recent paper from Oka et al describes how interrupting normal mitophagic mitochondrial DNA degradation after pressure overload can activate Toll-like receptor-9 mediated innate immunity, causing myocardial inflammation that contributes to cardiomyopathic decompensation. Circulation Research
The revelation that bacterial DNA potently stimulates the immune system anticipated by a handful of years the discovery of innate immunity mediated by pattern recognition receptors (PRR), including the Toll-like receptors (TLR). 1 TLR-9 is the prototypical TLR, 2 but a total of 10 human TLR are known (12 in the mouse). Recognizing foreign DNA and RNA is the specific function of the subfamily of nucleic acid-sensing TLR (TLR-3, -7, -8, and -9), which are further distinguished by subcellular localization to endosomes, enabling their specific surveillance for internalized foreign nucleic acids. Innate immune responses mediated by nucleic acid-sensing TLRs thus establishes an initial barrier to microbial and viral invasion; DNA or RNA released from captured and degraded microbes is sensed by TLR-rich cells and triggers cytokine release (Figure) . The endosomal TLR system acts in parallel with a more broadly expressed cytosolic PRR system that recognizes foreign nucleic acids of infecting microbes and responds by transcriptionally inducing interferon production, 3 and with the inflammasome complex that activates caspase 1/interleukin converting enzyme. 4 In a recent issue of Nature, Oka and colleagues uncover a potent role for TLR-9 mediated inflammation in pressure overload hypertrophy decompensation. 5 The heart responds to hemodynamic overload through genetic reprogramming and tissue/chamber remodeling that is initially compensatory. These measures fail over time, leading to cardiac dilatation and failure. The mechanisms for hypertrophy decompensation are unclear; programmed cell death, disturbances in calcium handling or ␤-adrenergic responsiveness, and matrix remodeling have all been implicated. What has never been satisfactorily addressed in why hypertrophy decompensation elicits myocardial inflammation, and whether this inflammation is cause or consequence of heart failure. Oka et al observed that myocardial inflammation in failing hypertrophied hearts (8 -10 weeks after surgical transverse aortic banding; TAC) was associated with increased mitochondrial DNA in autolysomes, and with diminished expression of DNase II. DNase II is the lysosomal-localized acidic endonuclease responsible for degrading both bacterial DNA delivered by endosomes and mitochondrial DNA delivered by autophagic vesicles (Figure) . The authors postulated that decreased DNase II and accelerated mitochondrial turnover were responsible for accumulation of generally intact mitochondrial DNA that could activate TLR-9, inducing inflammation and causing heart failure. An elegant series of experiments examined both critical mediators, DNase II and TLR-9: Cardiomyocyte-specific ablation of DNase II had little effect on normal hearts. However, as early as 2 days after TAC cardiac DNase II null mice showed evidence of mitochondrial DNA in autolysosomes, induction of cytokine gene expression, and myocardial inflammation. Ten days after TAC, cardiac DNase II null mice developed (in addition to myocardial inflammation) adverse chamber and myocardial remodeling, contractile dysfunction, and pulmonary congestion. Consequently, 4 weeks after TAC Ϸ50% of cardiac DNase II null mice were dead, compared with only Ϸ15% of the floxed controls. These results point to lysosomal DNase II as a critical protective factor that processes mitochondrial DNA during hypertrophic remodeling, preventing its activation of the innate immune response. The authors followed with studies showing that TLR-9 is responsible for reacting with the mitochondrial DNA: Blockade of TLR-9 recognition of mitochondrial DNA with an inhibitory oligodeoxynucleotide improved the cardiac DNase II null response to TAC, and genetic ablation of TLR-9 diminished myocardial inflammation and delayed functional decompensation of pressure overload hypertrophy in otherwise normal mice.
TLR-9 recognizes unmethylated CpG oligodeoxynucleotides that are more prevalent in bacterial and viral DNA than mammalian genomic DNA. 6 Because modern mitochondria are descended from primordial ␣-proteobacterial endosymbionts 7 and have their own circular genomes, 8 and bacterial DNA share various structural motifs, including a high prevalence of unmethylated CpG sequences. 9, 10 The molecular similarities between ancestral microbial DNA retained by modern mitochondria on one hand, and DNA of potentially pathogenic contemporary bacteria on the other, poses a biological dilemma for mammalian cells: how to preserve an invaluable innate immune response without constantly reacting to endogenous mitochondrial genomes. This is a highly specific form of the self/nonself discrimination problem that generally applies to immune systems. Because DNA sequence in the form of unmethylated CpGs is of limited value for self/nonself discrimination, the innate system makes the decision to trigger immune responses based not on "what" is the specific DNA sequence, but on "where" the offending DNA is encountered. TLR-9 is located primarily on endosomes, with the DNA recognition domains pointing toward the endosomal lumen. The functional imperative for endosomal localization of TLR-9 is so strong that proteolytic cleavage of TLR-9 within endosomes is required for full nucleic acid recognition and association with its signaling adaptor protein MyD88. 11, 12 Thus, extracellular microbes are engulfed by phagocytosis, endocytosed, and compartmentalized within TLR-9 containing endosomes where their DNA is recognized and triggers an appropriate immune reaction via induction of cytokines (Figure) . Once delivered to the acidic environment of the lysosome, microbial DNA is degraded by the acidic endonuclease, DNase II. Given the similarities between microbial and mitochondrial DNA, the problem is how to dispose of damaged or senescent mitochondria without activating this innate immune response; the evolutionary solution appears to have been mitophagy. Mitophagy is the unique mechanism by which cells normally eliminate dysfunctional mitochondria. Through mechanisms that are still incompletely understood, dysfunctional or depolarized mitochondria are recognized by double-membrane phagophores. The enlarging phagophore engulfs the targeted mitochondrion, creating a closed autophagosome that ultimately merges with a lysosome (to form the autophagosome), delivering the mitochondrion for degradation (Figure) . This mitochondrial degradative pathway circumvents the microbial endosomal pathway. Thus, mutually exclusive compartmentalization sequesters mitochondrial DNA well away from TLR-9.
The current and previous studies illustrate how disrupting mitophagy, and consequent escape of mitochondrial DNA from normal sequestration mechanisms, can activate TLR-9 dependent immune responses. Mitochondrial-derived factors capable of eliciting innate PRR immune responses, so-called DAMPs (damage-associated molecular patterns), contribute to a posttraumatic sepsis-like (but bacterially sterile) syndrome called systemic inflammatory response syndrome, and to associated shock lung. 13 In this condition mitochondrial DNA is released into plasma of human trauma victims, and CpG sequences activate TLR-9 and downstream p38 signaling. Furthermore, mitochondrial DAMPs were sufficient to induce similar lung inflammation and cytokine production in rats. Likewise, endogenous (genomic or mitochondrial) DNA that escapes normal degradation is implicated in juvenile idiopathic arthritis, or Still's disease, 14, 15 and direct intraarticular introduction of mitochondrial or bacterial DNA is sufficient to replicate the polyarthritis phenotype. 16 Thus, accumulating data support an important role for mitochondrial DNA misrecognized as foreign due to loss of normal compartmentalization in multiple inflammatory diseases.
The findings of Oka and colleagues extend the general paradigm described above to cardiac remodeling. Their results are compelling, although the potential confounder of myocardial toxicity induced by the high-expressing Myh6-Cre transgene they used is not controlled for in this work; 17 it is preferable to include Cre-positive control mice to identify Cre effects, rather than relying exclusively on floxed allele mice as controls. Nevertheless, the data strongly support a general role for innate immunity, and specifically implicate DNase II, mitochondrial DNA, and TLR-9 signaling in myocardial inflammation linked to decompensation of pressure overload hypertrophy. Two new questions arise: First, is TLR-9 the only path for activation of innate immunity by nonsequestered toxic mitochondrial DNA? The observation that genetic deletion of TLRs impairs, but does not completely prevent, innate immune responses to foreign nucleic acids 18, 19 led to the discovery of a functionally overlapping nonendosomal PRR system, the cytosolic retinoic acidinducible gene-I like receptors family of RNA-sensing receptors. 20 More recently, an incompletely characterized cytosolic DNA-sensing PRR pathway was also uncovered. 21 It is likely that mitochondrial DNA released into the cytosol from congested autolysosomes can activate this parallel system leading to innate immune activation. This raises the second question: What is the role of mitochondrial DNA in myocardial inflammation provoked by other forms of cardiac injury? Sublethal or lethal cardiomyocyte injury from ischemia, toxins, or viral infection has the potential both to induce mitochondrial autophagy and to release mitochondrial DNA into the cytoplasm. The combination of DAMPs released from necrotic cardiomyocytes may activate the same molecular mechanisms identified for posttraumatic systemic inflammatory response syndrome. 13 Answers to these questions will lay the foundation for therapeutic interventions directed at suppressing the innate immune response to mitochondrial DNA. Meanwhile, the confluence of molecular mediators elucidated by Oka and colleagues has already expanded the roles of cardiac mitochondria and the innate immune system as harbingers of heart failure.
